tretazicar has been researched along with Cytomegalovirus in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doshi, R; Green, NK; Kerr, DJ; McNeish, IA; Searle, PF; Young, LS | 1 |
| Bhide, SA; Harrington, KJ; Melcher, AA; Menghistu, T; Pandha, HS; Searle, PF; Twigger, KR; Vile, RG; White, CL | 1 |
| James, ND; Latham, JP; Mautner, V; Searle, PF | 1 |
3 other study(ies) available for tretazicar and Cytomegalovirus
| Article | Year |
|---|---|
Immune enhancement of nitroreductase-induced cytotoxicity: studies using a bicistronic adenovirus vector.
Topics: Adenocarcinoma; Adenoviruses, Human; Adjuvants, Immunologic; Animals; Antineoplastic Agents, Alkylating; Aziridines; Bystander Effect; Colorectal Neoplasms; Combined Modality Therapy; Cytomegalovirus; Defective Viruses; Drug Resistance, Neoplasm; Escherichia coli Proteins; Female; Genes; Genes, Synthetic; Genetic Therapy; Genetic Vectors; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Immunotherapy; Mesothelioma; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Nitroreductases; Prodrugs; Specific Pathogen-Free Organisms; Tumor Cells, Cultured | 2003 |
Escherichia coli nitroreductase plus CB1954 enhances the effect of radiotherapy in vitro and in vivo.
Topics: Animals; Apoptosis; Aziridines; Cell Line, Tumor; Combined Modality Therapy; Cytomegalovirus; DNA Fragmentation; Escherichia coli; Female; Flow Cytometry; Genetic Therapy; Genetic Vectors; Mice; Mice, Nude; Neoplasm Transplantation; Nitroreductases; Ovarian Neoplasms; Radiation-Sensitizing Agents; Transduction, Genetic | 2008 |
Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Topics: Adenoviridae; Androgens; Antineoplastic Agents; Aziridines; Cell Survival; Colonic Neoplasms; Coloring Agents; Cytomegalovirus; Enhancer Elements, Genetic; Genetic Therapy; Genetic Vectors; Green Fluorescent Proteins; Humans; Jurkat Cells; Kinetics; Luciferases; Luminescent Proteins; Male; Oxazines; Polymerase Chain Reaction; Prodrugs; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Recombinant Fusion Proteins; Tissue Kallikreins; Transfection; Tumor Cells, Cultured; Urinary Bladder Neoplasms; Xanthenes | 2000 |